Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein, +18

Cancer Cell

Molecular PharmacologyMutant Bcr-ablMedicineSelective InhibitorMolecular Biology +3

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke, +27

Nature

Molecular PharmacologyDrug TargetMedicineAtp-binding-site InhibitorsAnti-cancer Agent +3

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Sandra W. Cowan‐Jacob, Gabriele Fendrich, Paul W. Manley, +4

Structure

Crystal StructureBiochemistryC-src ActivationNatural SciencesC-src Complex +6

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Sandra W. Cowan‐Jacob, Gabriele Fendrich, Andreas Floersheimer, +7

Acta Crystallographica Section D Biological Crystallography

Imatinib-resistant PatientsMutant Abl KinaseHematological MalignancyStructural Biology ContributionsMedicine +10

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Paul W. Manley, Peter Drueckes, Gabriele Fendrich, +7

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

Drug TargetMedicineReceptor Tyrosine KinaseExtended Kinase ProfileAnti-cancer Agent +6

Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib

Navratna Vajpai, André Strauss, Gabriele Fendrich, +4

Journal of Biological Chemistry

EngineeringStructural BioinformaticsMolecular BiologySolution ConformationsAbl Kinase +18

Binding or Bending: Distinction of Allosteric Abl Kinase Agonists from Antagonists by an NMR-Based Conformational Assay

Wolfgang Jahnke, Robert M. Grotzfeld, Xavier Pellé, +8

Journal of the American Chemical Society

Drug TargetMolecular BiologyAllosteric InhibitorsChemical BiologyMedicinal Chemistry +14

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein, +18

Cancer Cell

Molecular PharmacologyMutant Bcr-ablMedicineSelective InhibitorMolecular Biology +3

Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of phospholipase A2. Structural revision of duramycin and cinnamycin.

Andreas Fredenhagen, Gabriele Fendrich, F. Märki, +4

The Journal of Antibiotics

Nonlinear Broensted correlations: The roles of resonance, solvation, and changing transition-state structure

William P. Jencks, Steven R. Brant, Joseph R. Gandler, +2

Journal of the American Chemical Society

Relaxation ProcessEngineeringChemical AnalysisAltmetric Attention ScoreOrganic Chemistry +20